AVALO THERAPEUTICS, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
AVALO THERAPEUTICS, INC. (AVTX) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $94.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-02.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2022-03-02
- AVALO THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2020-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2020-06-30 was $94.00K, a 420.57% increase year-over-year.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2019-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2020 was $94.00K, a 176.80% increase from fiscal 2019.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2019 was $33.96K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month as first filed | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month as first filed | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month as first filed | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $0.00 derived: sum of 2 quarters · filed 2022-03-02 | $94.00K derived: sum of 3 quarters · filed 2022-03-02 | $94.00K 10-K · filed 2022-03-02 | $93.87K 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $94.00K derived: sum of 2 quarters · filed 2021-11-09 | $94.00K 10-Q · filed 2021-11-09 | $93.87K 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $94.00K 10-Q · filed 2021-08-02 | $93.87K 10-Q · filed 2020-08-06 | $94.00K 10-Q · filed 2021-08-02 | $93.87K 10-Q · filed 2020-08-06 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $15.90K derived: sum of 2 quarters · filed 2021-03-08 | $33.96K derived: sum of 3 quarters · filed 2021-03-08 | $33.96K 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $15.90K 10-Q · filed 2020-11-09 | $33.96K derived: sum of 2 quarters · filed 2020-11-09 | $33.96K 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | $18.06K 10-Q · filed 2020-08-06 | $18.06K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |